newsfilter
← Latest News
GlobeNewswire·

Voyager Reports Third Quarter 2026 Financial and Operating Results

- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter